Current and emerging treatment options for hairy cell leukemia

References

• CampoESwerdlowSHHarrisNLPileriSSteinHJaffeESThe 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood2011117195019503221300984
   PubMed Web of Science ®Google Scholar
• CannonTMobarekDWeggeJTabbaraIAHairy cell leukemia: current conceptsCancer Invest200826886086518798068
   PubMed Web of Science ®Google Scholar
• TiacciETrifonovVSchiavoniGBRAF mutations in hairy-cell leukemiaN Engl J Med2011364242305231521663470
   PubMed Web of Science ®Google Scholar
• XiLAronsENavarroWBoth variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutationBlood2012119143330333222210875
   PubMed Web of Science ®Google Scholar
• BermanEHellerGKempinSGeeTTranLLClarksonBIncidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2aBlood19907548398452302457
   PubMed Web of Science ®Google Scholar
• GreverMKopeckyKFoucarMKRandomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup studyJ Clin Oncol19951349749827707126
   PubMed Web of Science ®Google Scholar
• FedericoMFrassoldatiALamparelliTLong-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian cooperative group for HCLAnn Oncol1994587257317826905
   PubMed Web of Science ®Google Scholar
• ChadhaPRademakerAWMendirattaPTreatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experienceBlood2005106124124615761021
   PubMed Web of Science ®Google Scholar
• ElseMDeardenCEMatutesELong-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosisBr J Haematol2009145673374019344416
   PubMed Web of Science ®Google Scholar
• MaloiselFBenboubkerLGardembasMLong-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patientsLeukemia2003171455112529659
   PubMed Web of Science ®Google Scholar
• ZinzaniPLTaniMMarchiELong-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosineHaematologica200489330931315020269
   PubMed Web of Science ®Google Scholar
• López-RubioMDa SilvaCLoscertalesJHairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish cooperative group on chronic lymphocytic leukemia (GELLC)Leuk Lymphoma20145551007101223885799
   PubMed Web of Science ®Google Scholar
• JonesGParry-JonesNWilkinsBElseMCatovskyDRevised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*Br J Haematol2012156218619522111844
   PubMed Web of Science ®Google Scholar
• RobakTBłasińska-MorawiecMKrykowskiE2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemiaLeuk Lymphoma1996221–21071118724536
   PubMed Web of Science ®Google Scholar
• LauriaFBocchiaMMarottaGRaspadoriDZinzaniPLRondelliDWeekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia: a new treatment schedule effective and safer in preventing infectious complicationsBlood1997895183818399057674
   PubMed Web of Science ®Google Scholar
• RobakTJamroziakKGora-TyborJCladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the polish adult leukemia group (PALG) of a prospective, randomized, multicenter trialBlood200710993672367517209059
   PubMed Web of Science ®Google Scholar
• JuliussonGHeldalDHippeESubcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemiaJ Clin Oncol19951349899957707128
   PubMed Web of Science ®Google Scholar
• von RohrASchmitzSFTichelliASwiss Group for Clinical Cancer Research (SAKK), Bern SwitzerlandTreatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II studyAnn Oncol200213101641164912377655
   PubMed Web of Science ®Google Scholar
• DeardenCEElseMCatovskyDLong-term results for pentostatin and cladribine treatment of hairy cell leukemiaLeuk Lymphoma201152suppl 2212421599603
   PubMed Web of Science ®Google Scholar
• EllisonDJSharpeRWRobbinsBAImmunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemiaBlood19948412431043157994047
   PubMed Web of Science ®Google Scholar
• MatutesEMeeusPMcLennanKCatovskyDThe significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up studyBr J Haematol19979823753839266936
   PubMed Web of Science ®Google Scholar
• BengioRNarbaitzMISarmientoMAPalaciosMFScolnikMPComparative analysis of immunophenotypic methods for the assessment of minimal residual disease in hairy cell leukemiaHaematologica200085111227122911064481
   PubMed Web of Science ®Google Scholar
• SausvilleJESalloumRGSorbaraLMinimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain geneAm J Clin Pathol2003119221321712579991
   PubMed Web of Science ®Google Scholar
• TallmanMSHakimianDKopeckyKJMinimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapseClin Cancer Res1999571665167010430066
   PubMed Web of Science ®Google Scholar
• WheatonSTallmanMSHakimianDPetersonLMinimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosineBlood1996874155615608608247
   PubMed Web of Science ®Google Scholar
• Garnache OttouFChandesrisMOLhermitteLPeripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patientsBr J Haematol20141661505924661013
   PubMed Web of Science ®Google Scholar
• GerrieASZypchenLNConnorsJMFludarabine and rituximab for relapsed or refractory hairy cell leukemiaBlood201211991988199122223825
   PubMed Web of Science ®Google Scholar
• RavandiFO’BrienSJorgensenJPhase 2 study of cladribine followed by rituximab in patients with hairy cell leukemiaBlood2011118143818382321821712
   PubMed Web of Science ®Google Scholar
• CervettiGGalimbertiSAndreazzoliFRituximab as treatment for minimal residual disease in hairy cell leukaemiaEur J Haematol200473641241715522063
   PubMed Web of Science ®Google Scholar
• CervettiGGalimbertiSAndreazzoliFRituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-upBr J Haematol2008143229629818710384
   PubMed Web of Science ®Google Scholar
• HabermannTMAndersenJWCassilethPABennettJMOkenMMSequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemiaBr J Haematol19928044664711581231
   PubMed Web of Science ®Google Scholar
• SavenABurianCKoziolJAPiroLDLong-term follow-up of patients with hairy cell leukemia after cladribine treatmentBlood1998926191819269731048
   PubMed Web of Science ®Google Scholar
• GoodmanGRBurianCKoziolJASavenAExtended follow-up of patients with hairy cell leukemia after treatment with cladribineJ Clin Oncol200321589189612610190
   PubMed Web of Science ®Google Scholar
• JehnUBartlRDietzfelbingerHHaferlachTHeinemannVAn update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosineLeukemia20041891476148115229616
   PubMed Web of Science ®Google Scholar
• GreverMRHow I treat hairy cell leukemiaBlood20101151212819843881
   PubMed Web of Science ®Google Scholar
• ElseMDeardenCEMatutesERituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrenceLeuk Lymphoma201152suppl 2757821504288
   PubMed Web of Science ®Google Scholar
• BurottoMStetler-StevensonMAronsEZhouHWilsonWKreitmanRJBendamustine and rituximab in relapsed and refractory hairy cell leukemiaClin Cancer Res201319226313632124097860
   PubMed Web of Science ®Google Scholar
• BenzRStussiGFehrJInterferon as an alternative to purine analogues in the treatment of hairy cell leukaemiaBr J Haematol2010148466466519814738
   PubMed Web of Science ®Google Scholar
• SeymourJFEsteyEHKeatingMJKurzrockRResponse to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosineLeukemia1995959299327769859
   PubMed Web of Science ®Google Scholar
• ForconiFSozziECenciniEHairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behaviorBlood2009114214696470219667403
   PubMed Web of Science ®Google Scholar
• TiacciESchiavoniGForconiFSimple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutationBlood2012119119219522028477
   PubMed Web of Science ®Google Scholar
• MatutesEWotherspoonABrito-BabapulleVCatovskyDThe natural history and clinico-pathological features of the variant form of hairy cell leukemiaLeukemia200115118418611243388
   PubMed Web of Science ®Google Scholar
• NaratSGandlaJDoganAMehtaASuccessful treatment of hairy cell leukemia variant with rituximabLeuk Lymphoma20054681229123216085567
   PubMed Web of Science ®Google Scholar
• QuachHJanuszewiczHWestermanDComplete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximabHaematologica200590supplECR2616266917
   PubMedGoogle Scholar
• YoshidaTMiharaKSugiharaSSplenectomy followed by administration of rituximab is useful to treat a patient with hairy cell leukemia-variantAnn Hematol201392571171323183878
   PubMed Web of Science ®Google Scholar
• KreitmanRJWilsonWCalvoKRCladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemiaClin Cancer Res201319246873688124277451
   PubMed Web of Science ®Google Scholar
• KreitmanRJWilsonWHBergeronKEfficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemiaN Engl J Med2001345424124711474661
   PubMed Web of Science ®Google Scholar
• KreitmanRJSquiresDRStetler-StevensonMPhase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignanciesJ Clin Oncol200523276719672916061911
   PubMed Web of Science ®Google Scholar
• DietrichSGlimmHAndrulisMvonKCHoADZenzTBRAF inhibition in refractory hairy-cell leukemiaN Engl J Med2012366212038204022621641
   PubMed Web of Science ®Google Scholar
• PeyradeFReDGinetCLow-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutationHaematologica2013982e20e2223300174
   PubMed Web of Science ®Google Scholar
• KreitmanRJWilsonWHWhiteJDPhase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignanciesJ Clin Oncol20001881622163610764422
   PubMed Web of Science ®Google Scholar
• KreitmanRJStetler-StevensonMMarguliesIPhase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemiaJ Clin Oncol200927182983299019414673
   PubMed Web of Science ®Google Scholar
• AronsEStetler-StevensonMWilsonWHFitzGeraldDJPPastanIPharmacokinetic analysis of response in hairy cell leukemia treated by anti-CD22 recombinant immunotoxin moxetumomab pasudotoxBlood2013122212871
   Web of Science ®Google Scholar
• FollowsGASimsHBloxhamDMRapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenibBr J Haematol2013161115015323278307
   PubMed Web of Science ®Google Scholar
• ParkJHChungSSChungYRPhase II trial of the BRAF inhibitor, vemurafenib, in patients with braf mutant relapsed or refractory hairy cell leukemiaBlood2013122212876
   Web of Science ®Google Scholar
• ParkJHChungSSChungYRVemurafenib has potent antitumor activity in patients with relapsed/refractory BRAF mutant hairy cell leukemiaBlood20141242424829207
   PubMed Web of Science ®Google Scholar
• TiacciEDe CaroliLZinzaniPLEfficacy and safety of the BRAF inhibitor vemurafenib in hairy cell leukemia patients refractory to or relapsed after purine analogs: a phase-2 Italian clinical trialBlood2014124150
   Web of Science ®Google Scholar
• SaschaDPircherAAndrulisMBRAF inhibition in hairy cell leukemia: multicentre experience of 21 patients treated with vemurafenibBlood20141243634
   Web of Science ®Google Scholar
• LitoPRosenNSolitDBTumor adaptation and resistance to RAF inhibitorsNat Med201319111401140924202393
   PubMed Web of Science ®Google Scholar
• LacoutureMEDuvicMHauschildAAnalysis of dermatologic events in vemurafenib-treated patients with melanomaOncologist201318331432223457002
   PubMed Web of Science ®Google Scholar
• AwadMMSullivanRJDabrafenib in combination with trametinib for the treatment of metastatic melanomaExpert Rev Clin Pharmacol201581253325473943
   PubMed Web of Science ®Google Scholar
• PettirossiVSantiAImperiEBRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent anti-leukemic activityBlood201412581207121625480661
   PubMed Web of Science ®Google Scholar
• BadarTBurgerJAWierdaWGO’BrienSIbrutinib: a paradigm shift in management of CLLExpert Rev Hematol20147670571725387837
   PubMed Web of Science ®Google Scholar
• HerreraAFJacobsenEDIbrutinib for the treatment of mantle cell lymphomaClin Cancer Res201420215365537125361916
   PubMed Web of Science ®Google Scholar
• SivinaMKreitmanRJAronsERavandiFBurgerJAThe Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approachBr J Haematol2014166217718824697238
   PubMed Web of Science ®Google Scholar
• JonesJAAndritsosLLucasDLozanskiGHutchinsonTPreliminary safety and efficacy of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (IBR) in patients (pts) with hairy cell leukemia (HCL)J Clin Oncol2014327063
   Web of Science ®Google Scholar
• JonesJAAndritsosLRavandiFSafety and efficacy of the Bruton tyrosine kinase inhibitor Ibrutinib in patients with hairy cell leukemia: interim results of a Phase II study Abstract S790Presented at EHA20June 2015
   Google Scholar